Adipotide (FTPP) is a synthetic dual-domain peptidomimetic engineered to destroy the capillary blood supply of white adipose tissue through targeted endothelial apoptosis. Its homing sequence binds to prohibitin and annexin A2 on adipose vasculature; its proapoptotic domain triggers mitochondrial collapse in bound cells. Research on Adipotide spans:
- Adipose tissue biology,
- Metabolic modelling,
- Angiogenesis research, and
- Oncology
Introduction
Obesity affects over one billion people globally, and despite decades of pharmacological investment, the pipeline of approved interventions remains remarkably narrow.
Obesity research has spent decades chasing hormonal levers. These include GLP-1 receptors, leptin signalling, and insulin sensitivity. The compounds that dominate the conversation all work through metabolic or neuroendocrine pathways. They modify appetite, slow gastric emptying, and shift fuel partitioning.
Adipotide does something categorically different.
Instead of interfering with how the body regulates energy, it goes directly after the infrastructure that keeps white fat tissue alive. The concept is to destroy its blood supply. That precision is exactly what has generated so much sustained interest.
What makes it genuinely interesting is not just what it does in animal models, but what it reveals about the biology of fat tissue itself and the broader possibility of vascular zip-code targeting as a precision research strategy.
This article covers Adipotide’s structure and dual-domain mechanism. It will also talk about the key experimental models and what they showed, and where the research is currently heading.
Disclaimer: Adipotide (FTPP) is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This content is for informational purposes only. Always consult a licensed medical professional before making any health-related decisions.
What Is Adipotide and How Is It Structured?
In the peer-reviewed literature, Adipotide circulates under several designations (FTPP, TP01, and Prohibitin-Targeting Peptide-1). Each one of them reflects a different aspect of its structure or mechanism. It is a synthetically engineered molecule that mimics peptide function while being structurally optimised for:
- improved stability,
- selectivity, or
- pharmacokinetics (compared to natural peptides)
The peptide has a homing Sequence (CKGGRAKDC) that targets prohibitin (PHB) and annexin A2 (ANXA2). Both are proteins selectively expressed on endothelial cells supplying white adipose tissue.
Then it has the Proapoptotic Sequence (D(KLAKLAK)₂) that disrupts mitochondrial membrane integrity, triggering apoptosis in the bound cell.
The full compound has a molecular weight of approximately 2,600 Da. Research-grade preparations typically exceed 99% purity.
Why Prohibitin and Annexin A2?
Receptor targeting is what makes Adipotide conceptually distinct. Prohibitin is a multifunctional protein involved in mitochondrial biogenesis, cell cycle regulation, and membrane signalling. While expressed broadly at low levels, its surface presentation on vascular endothelial cells appears to be markedly elevated in white adipose tissue. On the other hand, Annexin A2 plays a role in cell surface receptor organisation and endosomal trafficking. The PHB/ANXA2 complex on adipose capillary endothelium is the molecular address Adipotide is built to find.
How Does Adipotide’s Mechanism Work?
Think of the mechanism as a two-step guided missile. The homing sequence navigates to a specific tissue’s blood supply while the proapoptotic payload that destroys the endothelial cells it binds to. The consequence is a collapse of the microvasculature supplying white adipose tissue. This leaves adipocytes deprived of oxygen and nutrients.
It is important to note that this mechanism is considered irreversible at the level of the targeted endothelial cells. Unlike hormonal interventions that modulate ongoing metabolic signalling, Adipotide’s proapoptotic action eliminates the structural tissue it targets. This is both what makes the approach scientifically compelling and what has driven caution around its translational development.
What Have Experimental Models Shown?
The Kolonin Mouse Study (2004) — Proof of Concept
The foundational Adipotide research was published in Nature Medicine by Kolonin et al. in 2004. In obese mouse models, researchers identified the CKGGRAKDC motif and demonstrated that it homes selectively to white adipose vasculature. When conjugated to the D(KLAKLAK)₂ proapoptotic domain and administered to diet-induced obese mice for 28 days, the compound produced a marked reduction in body mass (almost 30%) in obese animals.
The Barnhart Primate Study (2011) — The Landmark Data
The research that moved Adipotide from an interesting rodent finding to serious scientific attention was the Barnhart et al. 2011 study published in Science Translational Medicine. This was a nonhuman primate study using spontaneously obese Old World monkeys. Now, this was a model considered closer to human metabolic physiology than rodents.
Key findings from the primate study:
- At the optimised subcutaneous dose of 0.43 mg/kg administered daily over 28 days, ten obese rhesus females recorded an average 11% body weight reduction alongside a 39% decrease in white adipose tissue deposits.
- Insulin resistance improved markedly
These numbers were significant enough to prompt the authors to describe Adipotide as a prototype for a new class of anti-obesity compounds.
What Scientific Controversies Surround Adipotide Research?
What most summaries of Adipotide leave out is the published scientific debate that followed the 2011 primate study.
One of them was a commentary in Science Translational Medicine (2012) that raised the possibility that the observed weight loss in monkeys might reflect a direct appetite-suppressing effect rather than the hypothesised vascular adipose mechanism.
The Kidney Toxicity Finding — Why Clinical Development Stalled
The other question raised was by the primate study, which also documented what became the primary safety concern with Adipotide. At experimentally determined optimal doses, monkeys across three species displayed predictable and reversible changes in renal proximal tubule function. The authors noted these changes were considered reversible at therapeutic doses, but the kidney toxicity signal was sufficient to halt advancement toward human clinical trials.
Both the above findings and controversies are what researchers must understand before designing any study protocol around Adipotide. The renal signal is real, documented in peer-reviewed literature, and is not a minor footnote.
Potential Applications Being Investigated in Research Models
1. Adipose Tissue Targeting Studies
Adipotide peptide is used in laboratory research to study targeted delivery mechanisms to white adipose tissue. Its specific nature of stopping blood flow to the vasculature makes it an awesome model compound. Researchers are fascinated by it as they can use it to investigate tissue-selective binding strategies.
2. Vascular Disruption Research
In experimental settings, Adipotide serves as a model for studying vascular-targeted apoptosis. Researchers see how the disruption of the blood supply affects tissue structure and cellular viability.
3. Metabolic Pathway Investigations
Adipotide is used in metabolic pathway investigations to study the relationship between adipose vascularisation and downstream signalling. This includes glucose handling, lipid metabolism, and adipokine secretion at the cellular level.
4. Peptide-Based Targeting Systems
The compound is also used as a reference in the development of peptide-based targeting systems. Its structure makes us understand selective binding to specific cellular receptors in laboratory conditions.
Note: All compounds mentioned are sold strictly for laboratory and research purposes only. Not intended for human or veterinary use.
Where Do Researchers Source Lab-Grade Adipotide?
For research-grade Adipotide, investigators typically look for independently third-party tested batches with a Certificate of Analysis (COA) confirmed per lot. Given the peptide’s structural complexity, purity and identity verification are non-negotiable for producing reproducible experimental results.
Researchers looking to buy Adipotide for preclinical and in vitro use will find BehemothLabz a trusted source of COA-verified, research-grade Adipotide. PureRawz also supplies Adipotide strictly for laboratory research, with batch-level documentation available. Both suppliers serve the research community with verified compound integrity.
Disclosure: This article contains sponsored links to BehemothLabz and/or PureRawz.co. Content is for informational purposes only and does not constitute medical advice or endorsement of any product for human use.
Risks and Limitations of Adipotide Research
This section is important reading for anyone following research on Adipotide.
Handling Precautions: Adipotide should be handled by trained laboratory personnel only, in a controlled research environment. Use appropriate personal protective equipment at all times. Avoid direct skin contact with reconstituted solutions.
Exposure Risks: Adipotide is a synthetic dual-domain peptidomimetic thought to induce apoptosis in prohibitin/annexin A2-expressing endothelial cells in preclinical models. No comprehensive human safety profile has been established.
Renal Toxicity Signal: The most significant safety finding in published literature is the renal proximal tubule changes documented in the Barnhart primate study. This is not a theoretical concern. Any research protocol involving Adipotide must include renal function monitoring.
Storage: Store lyophilised Adipotide at −20°C in a dry, dark environment. Protect from light, heat, and moisture. Reconstituted solutions should be handled under sterile conditions and used promptly or stored per institutional protocols.
Toxicity and Data Limitations: Chronic toxicity data for Adipotide are not available in the peer-reviewed literature. The primary published studies are short-duration (28-day) models in rodents and primates.
Regulatory Status: Adipotide is not FDA-approved for human or veterinary use in any formulation. It has not completed human clinical trials. Its development as a clinical candidate was halted following the renal toxicity findings in primates. All research use must comply with applicable institutional and regulatory frameworks.
Conclusion
Adipotide stands apart in the peptide research landscape. It’s not because its development path has been smooth, but because the scientific questions it opens are genuinely novel. The vascular zip-code approach it exemplifies, the prohibitin/annexin A2 receptor axis it targets, and the primate data it generated represent a coherent and independently significant contribution to our understanding of adipose tissue biology and precision vascular targeting.
Research remains early-stage. The renal toxicity signal is real and must be central to any protocol design. The mechanistic controversy around appetite suppression versus direct vascular action has not been definitively resolved.
What is clear is that Adipotide continues to attract serious researchers (in metabolic biology, angiogenesis, and oncology) precisely because what it does in animal models does not fit neatly into any existing pharmacological category. For laboratories following this compound, COA-verified, research-grade Adipotide is available from BehemothLabz for preclinical and in vitro research use.
Frequently Asked Questions
How does Adipotide differ from other fat-targeting research peptides?
Most metabolic research peptides operate through hormonal, enzymatic, or receptor-level metabolic pathways. Adipotide bypasses adipocyte biology entirely and instead targets the endothelial cells supplying white fat tissue with blood.
What did the primate study show about Adipotide?
The 2011 Barnhart et al. study in Science Translational Medicine found that obese rhesus monkeys treated with Adipotide for 28 days showed an average 11% reduction in body weight, a 39% decrease in white adipose tissue confirmed by MRI and DEXA, and a 36.2% reduction in insulin AUC. The study also identified reversible renal proximal tubule changes at therapeutic doses. This was the primary safety finding that halted clinical development.
Why was Adipotide clinical development discontinued?
Development was halted primarily due to renal proximal tubule toxicity identified in the primate study. The kidney toxicity profile was sufficient to prevent advancement to human trials.
Is Adipotide related to the vascular zip-code research concept?
Yes. Adipotide is one of the clearest in vivo demonstrations of the vascular zip-code principle. The idea is that different tissues display distinct endothelial receptor profiles that can be mapped and exploited for tissue-specific targeting. The CKGGRAKDC homing domain’s affinity for PHB/ANXA2 on adipose vasculature was identified through phage display and serves as a reference case study for researchers working on vascular homing agent design.
References
- Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine, 2004. https://pubmed.ncbi.nlm.nih.gov/15557121/
- Barnhart KF, Christianson DR, et al. A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys. Science Translational Medicine, 2011. https://www.science.org/doi/10.1126/scitranslmed.3002621
- Comment on Barnhart et al. Science Translational Medicine, 2012. https://www.science.org/doi/10.1126/scitranslmed.3003760
- Barnhart et al. Response to Comment. Science Translational Medicine, 2012. https://www.science.org/doi/10.1126/scitranslmed.3004103
- Daquinag AC, et al. Adipose tissue vasculature-targeting by a synthetic peptidomimetic. PLOS ONE, 2015. https://pubmed.ncbi.nlm.nih.gov/26061583/
All products mentioned are sold strictly for LABORATORY AND RESEARCH PURPOSES ONLY. Not for human or veterinary use.
